118 related articles for article (PubMed ID: 18942262)
1. [New therapeutic alternatives in migraine prophylaxis using histamine H3 receptor agonists].
Millán-Guerrero RO; Isais-Millán R
Gac Med Mex; 2008; 144(4):291-5. PubMed ID: 18942262
[TBL] [Abstract][Full Text] [Related]
2. [Subcutaneous histamine in migraine prophylaxis. Initial effects and long-term outcome].
Millán Guerrero R; Trujillo Hernández B; Tene CE
Neurologia; 2006 Mar; 21(2):55-9. PubMed ID: 16525910
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous histamine versus topiramate in migraine prophylaxis: a double-blind study.
Millán-Guerrero RO; Isais-Millán R; Barreto-Vizcaíno S; Gutiérrez I; Rivera-Castaño L; Trujillo-Hernández B; Baltazar LM
Eur Neurol; 2008; 59(5):237-42. PubMed ID: 18264012
[TBL] [Abstract][Full Text] [Related]
4. Nalpha-methyl histamine safety and efficacy in migraine prophylaxis: phase III study.
Millán-Guerrero RO; Isais-Millán R; Benjamín TH; Tene CE
Can J Neurol Sci; 2006 May; 33(2):195-9. PubMed ID: 16736729
[TBL] [Abstract][Full Text] [Related]
5. N alpha methyl histamine versus propranolol in migraine prophylaxis.
Millán-Guerrero RO; Isais-Millán R; Guzmán-Chávez B; Castillo-Varela G
Can J Neurol Sci; 2014 Mar; 41(2):233-8. PubMed ID: 24534036
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous histamine versus sodium valproate in migraine prophylaxis: a randomized, controlled, double-blind study.
Millán-Guerrero RO; Isais-Millán R; Barreto-Vizcaíno S; Rivera-Castaño L; Garcia-Solorzano A; López-Blanca C; Membrila-Maldonado M; Muñoz-Solis R
Eur J Neurol; 2007 Oct; 14(10):1079-84. PubMed ID: 17880560
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial.
Cady RK; Mathew N; Diener HC; Hu P; Haas M; Novak GP;
Headache; 2009 Feb; 49(2):216-26. PubMed ID: 19222595
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous histamine versus botulinum toxin type A in migraine prophylaxis: a randomized, double-blind study.
Millán-Guerrero RO; Isais-Millán S; Barreto-Vizcaíno S; Rivera-Castaño L; Rios-Madariaga C
Eur J Neurol; 2009 Jan; 16(1):88-94. PubMed ID: 19087155
[TBL] [Abstract][Full Text] [Related]
9. Nalpha-methylhistamine safety and efficacy in migraine prophylaxis: phase I and phase II studies.
Millán-Guerrero RO; Pineda-Lucatero AG; Hernández-Benjamín T; Tene CE; Pacheco MF
Headache; 2003 Apr; 43(4):389-94. PubMed ID: 12656710
[TBL] [Abstract][Full Text] [Related]
10. Histamine as a therapeutic alternative in migraine prophylaxis: a randomized, placebo-controlled, double-blind study.
Guerrero RO; Cárdenas MA; Ocampo AA; Pacheco MF
Headache; 1999 Sep; 39(8):576-80. PubMed ID: 11279974
[TBL] [Abstract][Full Text] [Related]
11. Open-label trial of cinnarizine in migraine prophylaxis.
Togha M; Ashrafian H; Tajik P
Headache; 2006 Mar; 46(3):498-502. PubMed ID: 16618269
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine.
Aurora SK; Rozen TD; Kori SH; Shrewsbury SB
Headache; 2009 Jun; 49(6):826-37. PubMed ID: 19545249
[TBL] [Abstract][Full Text] [Related]
13. Histamine in migraine and brain.
Alstadhaug KB
Headache; 2014 Feb; 54(2):246-59. PubMed ID: 24433203
[TBL] [Abstract][Full Text] [Related]
14. Placebo response in the prophylaxis of migraine: a meta-analysis.
Macedo A; Baños JE; Farré M
Eur J Pain; 2008 Jan; 12(1):68-75. PubMed ID: 17451980
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials.
Shuhendler AJ; Lee S; Siu M; Ondovcik S; Lam K; Alabdullatif A; Zhang X; Machado M; Einarson TR
Pharmacotherapy; 2009 Jul; 29(7):784-91. PubMed ID: 19558252
[TBL] [Abstract][Full Text] [Related]
16. Rapid responders to frovatriptan in acute migraine treatment: results from a long-term, open-label study.
Spierings EL; Keywood C
Pain Med; 2009; 10(4):633-8. PubMed ID: 19453958
[TBL] [Abstract][Full Text] [Related]
17. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
Mathew NT; Landy S; Stark S; Tietjen GE; Derosier FJ; White J; Lener SE; Bukenya D
Headache; 2009 Jul; 49(7):971-82. PubMed ID: 19486178
[TBL] [Abstract][Full Text] [Related]
18. The histamine H3 receptor: from gene cloning to H3 receptor drugs.
Leurs R; Bakker RA; Timmerman H; de Esch IJ
Nat Rev Drug Discov; 2005 Feb; 4(2):107-20. PubMed ID: 15665857
[TBL] [Abstract][Full Text] [Related]
19. Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis.
Goadsby PJ; Ferrari MD; Csanyi A; Olesen J; Mills JG;
Cephalalgia; 2009 Jul; 29(7):742-50. PubMed ID: 19222510
[TBL] [Abstract][Full Text] [Related]
20. Pathophysiological basis of migraine prophylaxis.
Galletti F; Cupini LM; Corbelli I; Calabresi P; Sarchielli P
Prog Neurobiol; 2009 Oct; 89(2):176-92. PubMed ID: 19654035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
